Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $10.7450 (3.57%) ($10.7450 - $10.7550) on Fri. Oct. 28, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.36% (three month average) | RSI | 60 | Latest Price | $10.7450(3.57%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FOLD declines -0.6% a day on average for past five trading days. | Weekly Trend | FOLD declines -0.3% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) IBB(54%) IWM(44%) IWO(44%) IWC(43%) IWN(42%) | Factors Impacting FOLD price | FOLD will decline at least -1.68% in a week (0% probabilities). VIXM(-13%) VXX(-11%) UUP(-8%) XLU(-3%) UNG(-2%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.68% (StdDev 3.36%) | Hourly BBV | 0.8 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $10.6(1.37%) | 10 Day Moving Average | $10.78(-0.32%) | 20 Day Moving Average | $10.74(0.05%) | To recent high | -15.9% | To recent low | 9.3% | Market Cap | $2.775b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |